Home > Insider Trading > Filing (0001725160-21-000120)

Filing Details

Accession Number:: 0001725160-21-000120
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-05 13:00:00
Reporting Period:: 2021-05-03

Accepted Time:: 2021-05-05 16:27:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1725160	Zentalis Pharmaceuticals Inc.	ZNTL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1807359	Epperly Melissa B,	C/O Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue, Suite 2201 New York NY 10018	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-05-03	350	$56.99	265,973	No	4	S	Direct
Common Stock	Disposition	2021-05-03	661	$58.04	265,312	No	4	S	Direct
Common Stock	Disposition	2021-05-03	950	$59.83	264,362	No	4	S	Direct
Common Stock	Disposition	2021-05-03	1,122	$60.14	263,240	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $56.56 to $57.47. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $57.64 to $58.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $59.05 to $60.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $60.05 to $60.37. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.